Feng Dechao, Li Dengxiong, Xiao Yuhan, Wu Ruicheng, Wang Jie, Zhang Chi
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Rehabilitation, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Chin J Cancer Res. 2023 Aug 30;35(4):424-430. doi: 10.21147/j.issn.1000-9604.2023.04.08.
Due to its lower risk of consequences when compared to a radical approach, focal treatment is a viable and minimally invasive option for treating specific localized prostate cancer. Although several recent good non-randomized trials have suggested that focused therapy may be an alternative choice for some patients, additional high-quality evidence is needed before it can be made widely available as a conventional treatment. As a result, we have summarized the most recent findings from the 38th Annual European Association of Urology Congress, one of the most renowned annual conferences in the area of urology, regarding focal ablation therapy for patients with localized prostate cancer. Additionally, we also provided clinical trials in progress for researchers to better understand the current research status of this field.
与根治性治疗方法相比，聚焦治疗导致不良后果的风险较低，因此是治疗特定局限性前列腺癌的一种可行且微创的选择。尽管最近有几项良好的非随机试验表明聚焦治疗可能是一些患者的替代选择，但在其能够作为常规治疗广泛应用之前，还需要更多高质量的证据。因此，我们总结了第38届欧洲泌尿外科学会年会（这是泌尿外科学领域最著名的年度会议之一）中关于局限性前列腺癌患者聚焦消融治疗的最新研究结果。此外，我们还提供了正在进行的临床试验，以便研究人员更好地了解该领域的当前研究状况。
